Therapeutic Development for Charcot-Marie-Tooth Disease

Page 1

Charcot-Marie-Tooth Disease – Pipeline Review, H1 2015 By RnRMarketResearch

Browse more reports on Pharmaceuticals at http://www.rnrmarketresearch.com/reports/lifesciences/pharmaceuticals Š http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441


Charcot-Marie-Tooth Disease – Pipeline Review, H1 2015 Global Markets Direct’s, ‘Charcot-Marie-Tooth Disease – Pipeline Review, H1 2015′, provides an overview of the Charcot-Marie-Tooth Disease’s therapeutic pipeline. Charcot-Marie-Tooth disease is one of the most common inherited disorders that affects to 1 in 2,500 people. It is a group of hereditary disorders that damage the nerves in your arms and legs. It affects both motor and sensory nerves of the body. The feature includes weakness of the foot and lower leg muscles, which may result in foot drop and a high-stepped gait with frequent tripping. It also often causes contractures. There are many forms of CharcotMarie-Tooth disease, including CMT1, CMT2, CMT3, CMT4, and CMTX. Complete report available at http://www.rnrmarketresearch.com/charcot-marietooth-disease-pipeline-review-h1-2015-market-report.html .

© http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441


Charcot-Marie-Tooth Disease – Pipeline Review, H1 2015 This report provides comprehensive information on the therapeutic development for Charcot-Marie-Tooth Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Charcot-Marie-Tooth Disease and special features on late-stage and discontinued projects. Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Š http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441


Charcot-Marie-Tooth Disease – Pipeline Review, H1 2015 Scope: • The report provides a snapshot of the global therapeutic landscape of Charcot-Marie-Tooth Disease. • The report reviews key pipeline products under drug profile section which includes product description, MoA and R&D brief, licensing and collaboration details & other developmental activities. • The report reviews key players involved in the therapeutics development for Charcot-Marie-Tooth Disease and enlists all their major and minor projects. • The report summarizes all the dormant and discontinued pipeline projects.

© http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441


Charcot-Marie-Tooth Disease – Pipeline Review, H1 2015 Reasons to Buy: • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies. • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. • Develop strategic initiatives by understanding the focus areas of leading companies. • Identify and understand important and diverse types of therapeutics under development for Charcot-Marie-Tooth Disease.

© http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441


Charcot-Marie-Tooth Disease – Pipeline Review, H1 2015

For more details contact Mr. Ritesh Tiwari : sales@rnrmarketresearch.com / +18883915441

RnRMarkertResearch RnRMarketResearch.com, an online repository of market research reports, offers in-depth analysis of over 5000 market segments. RnR Market Research library has syndicated reports by leading market research publishers across the globe.

Š http://www.rnrmarketresearch.com/ ; sales@RnRMarketResearch.com +1 888 391 5441


Turn static files into dynamic content formats.

Create a flipbook
Issuu converts static files into: digital portfolios, online yearbooks, online catalogs, digital photo albums and more. Sign up and create your flipbook.